Nexalin Technology (NASDAQ:NXL) Shares Up 2.9% – Should You Buy?

Nexalin Technology, Inc. (NASDAQ:NXL)’s stock price rose 2.9% on Monday . The company traded as high as $0.5149 and last traded at $0.4913. 202,584 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 261,259 shares. The stock had previously closed at $0.4775.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nexalin Technology in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Nexalin Technology Trading Down 4.1%

The company has a market capitalization of $10.16 million, a P/E ratio of -0.98 and a beta of 4.00. The firm’s 50 day moving average price is $0.42 and its two-hundred day moving average price is $0.46.

Nexalin Technology (NASDAQ:NXL) last released its earnings results on Friday, May 8th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Nexalin Technology had a negative net margin of 3,018.12% and a negative return on equity of 191.88%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million.

Institutional Trading of Nexalin Technology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Susquehanna International Group LLP acquired a new stake in Nexalin Technology in the 3rd quarter valued at about $57,000. Renaissance Technologies LLC increased its holdings in shares of Nexalin Technology by 119.2% during the 4th quarter. Renaissance Technologies LLC now owns 122,100 shares of the company’s stock worth $68,000 after acquiring an additional 66,400 shares during the last quarter. Geode Capital Management LLC raised its stake in Nexalin Technology by 23.4% in the 4th quarter. Geode Capital Management LLC now owns 150,274 shares of the company’s stock valued at $84,000 after acquiring an additional 28,454 shares during the period. Finally, PEAK6 LLC acquired a new stake in Nexalin Technology during the 4th quarter valued at $266,000. 0.65% of the stock is owned by institutional investors.

Nexalin Technology Company Profile

Nexalin Technology, Inc is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S.